MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.

To identify molecular determinants of histone deacetylase inhibitor (HDI) resistance, we selected HuT78 cutaneous T-cell lymphoma (CTCL) cells with romidepsin in the presence of P-glycoprotein inhibitors to prevent transporter upregulation. Resistant sublines were 250- to 385-fold resistant to romidepsin and were resistant to apoptosis induced by apicidin, entinostat, panobinostat, belinostat, and vorinostat. A custom TaqMan array identified increased insulin receptor (INSR) gene expression; immunoblot analysis confirmed increased protein expression and a four- to eightfold increase in mitogen-activated protein kinase (MAPK) kinase (MEK) phosphorylation in resistant cells compared with parental cells. Resistant cells were exquisitely sensitive to MEK inhibitors, and apoptosis correlated with restoration of proapoptotic Bim. Romidepsin combined with MEK inhibitors yielded greater apoptosis in cells expressing mutant KRAS compared with romidepsin treatment alone. Gene expression analysis of samples obtained from patients with CTCL enrolled on the NCI1312 phase 2 study of romidepsin in T-cell lymphoma suggested perturbation of the MAPK pathway by romidepsin. Immunohistochemical analysis of Bim expression demonstrated decreased expression in some skin biopsies at disease progression. These findings implicate increased activation of MEK and decreased Bim expression as a resistance mechanism to HDIs, supporting combination of romidepsin with MEK inhibitors in clinical trials.

[1]  M. Broggini,et al.  RAS/RAF/MEK inhibitors in oncology. , 2012, Current medicinal chemistry.

[2]  M. Gottesman,et al.  Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. , 2011, Molecular pharmaceutics.

[3]  A. Belfiore,et al.  Insulin receptor and cancer. , 2011, Endocrine-related cancer.

[4]  S. Digumarthy,et al.  BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. , 2011, Cancer discovery.

[5]  S. Steinberg,et al.  Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. , 2011, Blood.

[6]  M. Gottesman,et al.  Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. , 2011, Current pharmaceutical biotechnology.

[7]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[8]  J. Becker,et al.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Roth,et al.  Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim , 2010, PloS one.

[10]  James E. Bradner,et al.  Chemical Phylogenetics of Histone Deacetylases , 2010, Nature chemical biology.

[11]  S. Steinberg,et al.  Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphoma , 2010, British journal of haematology.

[12]  S. Steinberg,et al.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Ceri M. Wiggins,et al.  Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene‐targeted therapeutics , 2009, The FEBS journal.

[14]  Gabriel S. Eichler,et al.  Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database , 2009, Molecular Cancer Therapeutics.

[15]  Michael Bots,et al.  Rational Combinations Using HDAC Inhibitors , 2009, Clinical Cancer Research.

[16]  H. Prince,et al.  Clinical Studies of Histone Deacetylase Inhibitors , 2009, Clinical Cancer Research.

[17]  Wei-Guo Zhu,et al.  Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. , 2009, Neoplasia.

[18]  C. Paweletz,et al.  Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. , 2008, Cancer research.

[19]  R. Johnstone,et al.  Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin , 2008, Molecular Cancer Therapeutics.

[20]  V. Fantin,et al.  Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications , 2007, Clinical Cancer Research.

[21]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[22]  Mark J. Smyth,et al.  Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma , 2007, Proceedings of the National Academy of Sciences.

[23]  Julie A Hong,et al.  Apoptosis Induced by Depsipeptide FK228 Coincides with Inhibition of Survival Signaling in Lung Cancer Cells , 2007, Cancer journal.

[24]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[25]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[26]  Hisashi Yamada,et al.  Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile. , 2006, Leukemia research.

[27]  T. Fojo,et al.  Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176) , 2006, Clinical Cancer Research.

[28]  M. Kohno,et al.  Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. , 2006, Biochemical and biophysical research communications.

[29]  E. White,et al.  Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. , 2005, Cancer cell.

[30]  S. Bates,et al.  T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. , 2004, Blood.

[31]  G. Pagès,et al.  Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function , 2003, Oncogene.

[32]  S. Cook,et al.  Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim* , 2003, Journal of Biological Chemistry.

[33]  Minoru Yoshida,et al.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.

[34]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[35]  W. Wilson,et al.  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.

[36]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[37]  E. Sausville,et al.  P21-dependent G 1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 , 2000, British Journal of Cancer.

[38]  M. Grever,et al.  Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. , 1994, Molecular pharmacology.

[39]  M. Okuhara,et al.  FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. , 1994, The Journal of antibiotics.